Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 72-year-old man is evaluated prior to discharge from the hospital following an admission for highly symptomatic atrial fibrillation. His past medical history is significant for hypertension, hyperlipidemia, and type 2 diabetes mellitus. During hospitalization, his heart rate remained inadequately controlled despite maximum tolerated doses of metoprolol. The cardiology service initiated oral amiodarone for rhythm control, and the patient successfully converted to normal sinus rhythm. He is transitioning to outpatient care on his newly adjusted medication regimen, which includes amiodarone, metoprolol, apixaban, atorvastatin, and metformin. Which of the following tests are indicated for the routine baseline and ongoing monitoring of his new antiarrhythmic therapy? (Select all that apply)

  1. Thyroid-stimulating hormone (TSH) levelAnswer
  2. Hepatic aminotransferase levelsAnswer
  3. C
    Prothrombin time and international normalized ratio (PT/INR)
  4. D
    Monthly serum creatinine concentration
  5. E
    Annual low-dose chest computed tomography (CT)

Answer

The correct monitoring parameters are the Thyroid-stimulating hormone (TSH) level and Hepatic aminotransferase levels.
Amiodarone is a highly efficacious class III antiarrhythmic agent, but its clinical utility is often limited by significant extracardiac toxicities. Because the amiodarone molecule is heavily iodinated and structurally related to thyroid hormone, it frequently causes either hypothyroidism or hyperthyroidism. Consequently, a baseline TSH and periodic reassessments (typically every 6 months) are standard of care. Furthermore, amiodarone is hepatotoxic; baseline and ongoing periodic monitoring of hepatic aminotransferase levels are required to detect subclinical liver injury. Additional routine monitoring for amiodarone includes baseline chest radiography, pulmonary function testing, and regular ophthalmologic exams.

Step-by-Step Solution

1
Identify the newly prescribed high-risk pharmacotherapy.
The patient has been started on amiodarone for rhythm control of atrial fibrillation.
Different antiarrhythmic agents have distinct side effect profiles that dictate specific long-term monitoring strategies.
2
Determine the common systemic toxicities associated with amiodarone.
Amiodarone is associated with pulmonary toxicity, hepatotoxicity, thyroid dysfunction, and ocular deposits.
Understanding the organ systems affected determines which laboratory and diagnostic tests are required.
3
Select the corresponding baseline and periodic monitoring tests for these toxicities.
Appropriate monitoring includes TSH (for thyroid function) and hepatic aminotransferases (for hepatotoxicity).
These specific laboratory parameters must be checked at baseline and every 6 months to detect asymptomatic end-organ damage.

Key Concept

Baseline and periodic monitoring for amiodarone therapy includes thyroid function tests (TSH), liver function tests (aminotransferases), pulmonary function testing, and electrocardiography.
Estimated Time:1m 15s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic